Terms: = Brain cancer AND EML4, ENSG00000143924, 27436 AND Diagnosis
11 results:
1. A case of inflammatory myofibroblastic tumor harboring eml4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract] [Full Text] [Related]
2. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
3. Genomic and epigenomic re-categorization of congenital glioblastoma and desmoplastic infantile ganglioglioma.
Gilani A; Siddiq Z; Kissell E; Kasson J; Kleinschmidt-DeMasters BK
Childs Nerv Syst; 2023 Jul; 39(7):1861-1868. PubMed ID: 36707425
[TBL] [Abstract] [Full Text] [Related]
4. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract] [Full Text] [Related]
5. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract] [Full Text] [Related]
6. Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With eml4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.
Gong J; Gregg JP; Ma W; Yoneda K; Moore EH; Daly ME; Zhang Y; Williams MJ; Li T
J Natl Compr Canc Netw; 2019 Apr; 17(4):297-301. PubMed ID: 30959466
[TBL] [Abstract] [Full Text] [Related]
7. eml4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK
Christopoulos P; Endris V; Bozorgmehr F; Elsayed M; Kirchner M; Ristau J; Buchhalter I; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Warth A; Bischoff H; Schirmacher P; Stenzinger A; Thomas M
Int J Cancer; 2018 Jun; 142(12):2589-2598. PubMed ID: 29363116
[TBL] [Abstract] [Full Text] [Related]
8. [Atypical metastatic breast localization in lung cancer].
Serraille A; Barazzutti H; Greillier L; Barlesi F
Rev Mal Respir; 2015 Nov; 32(9):953-5. PubMed ID: 26037683
[TBL] [Abstract] [Full Text] [Related]
9. Long-lasting response to crizotinib in brain metastases due to eml4-ALK-rearranged non-small-cell lung cancer.
Kinoshita Y; Koga Y; Sakamoto A; Hidaka K
BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24022905
[TBL] [Abstract] [Full Text] [Related]
10. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
Yang P; Kulig K; Boland JM; Erickson-Johnson MR; Oliveira AM; Wampfler J; Jatoi A; Deschamps C; Marks R; Fortner C; Stoddard S; Nichols F; Molina J; Aubry MC; Tang H; Yi ES
J Thorac Oncol; 2012 Jan; 7(1):90-7. PubMed ID: 22134072
[TBL] [Abstract] [Full Text] [Related]
11. Incidentally proven pulmonary "ALKoma".
Osoegawa A; Nosaki K; Miyamoto H; Kometani T; Hirai F; Ondo K; Seto T; Sugio K; Choi YL; Soda M; Mano H; Ichinose Y
Intern Med; 2010; 49(6):603-6. PubMed ID: 20228600
[TBL] [Abstract] [Full Text] [Related]
